TA-65 and Aging Associated Microvascular Dysfunction

Sponsor
Medical College of Wisconsin
Study ID
NCT05598359
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Aging
  • Telomere Shortening
  • Vascular Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • TA-65 — DIETARY_SUPPLEMENT
    TA-65 is a purified small molecule extracted from Astragalus root
  • Placebo — OTHER
    Inactive formulation

Study Details

The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.

Key Dates

First listed
Oct 28, 2022
Start date
Jan 1, 2027
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: TA-65
    TA-65 (250 U) taken once per day
  • Placebo Comparator: Placebo
    Placebo taken once per day

Primary Outcome Measure

Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis [ Time Frame: 28 days ]

Central Contacts

Related Studies